Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 5OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Endostatins × Clear all
NCT03117335 2017-04-17

Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.

Phase 3 Completed
560 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02630264 2015-12-15

E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Guangzhou Double Bioproducts Co., Ltd

Phase 3 Unknown
540 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡